The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Trombolysis in Myocardial Infarctation 22 PROVE IT-TIMI 22 was a study that compared moderate regime of treatment with 40 mg/day of pravastatin against intense regime of 80 mg/day of atorvastatin, with the hypothesis that pravastatin was not inferior to atorvastatin, despite the lower power.
El Pravastatin or Atorvastatin Evaluation and Infection Therapy-Trombolysis in Myocardial Infarctation 22 PROVE IT-TIMI 22 fue un estudio que comparó el régimen moderado de tratamiento con 40 mg/día de pravastatina contra el régimen intenso de 80 mg/día de atorvastatina, con la hipótesis de que la pravastatina no sería inferior a la atorvastatina, a pesar de su menor potencia.
Os patrocinadores do estudo apostavam, portanto, nos efeitos pleiotrópicos da pravastatina.